Multiple reports describe results from research on a new anti-obesity medication intended to curb appetite and help burn calories. The articles highlight outcomes for patients given a 12 mg dose, saying they typically lose a substantial portion of their body weight over a defined period. One outlet reports that patients taking 12 mg lose more than a quarter of their body weight—28.3%—over 18 months. The same coverage translates that reduction into an estimated weight loss of 31.9 kg (about five stones), framing the effect as comparable to weight loss seen with lifestyle measures. The reporting is consistent in focusing on the 12 mg dosage, the 18-month follow-up period, and the magnitude of average weight loss. However, the provided excerpts do not include additional trial details such as study design, comparison groups, side effects, eligibility criteria, or whether results come from randomized trials versus observational follow-up. Overall, the sources align on the headline finding: a 12 mg regimen is associated with large average weight loss within 18 months in the studied population.
Study reports significant weight loss with 12 mg appetite-suppressing, calorie-burning drug
Multiple reports describe results from research on a new anti-obesity medication intended to curb appetite and help burn calories. The articles highlight outcomes for patients given a 12 mg dose, sayi...
- A new drug is reported to reduce appetite and support calorie burning.
- Patients receiving a 12 mg dose typically lose 28.3% of body weight.
- The weight-loss outcome is reported over an 18-month period.
- The 28.3% loss is estimated as 31.9 kg (about five stones) in the cited reporting.
Patients taking a 12mg dose typically lost more than a quarter of their body weight (28.3 per cent) in just 18 months - the equivalent of 31.9kg or 5 stones.
3 months agoPatients taking a 12mg dose typically lost more than a quarter of their body weight (28.3 per cent) in just 18 months - the equivalent of 31.9kg or 5 stones.
3 months ago
FDA authorizes Abbott’s Libre Duo 10 Day wearable for continuous glucose and ketone monitoring
The U.S. Food and Drug Administration has authorized Abbott’s Libre Duo 10 Day Continuous Dual Glucose-Ketone Monitoring...
Nepal–Tibet flash floods and landslides kill over 350, hundreds still missing
Flash floods and landslides strike along the Nepal–Tibet border, killing more than 350 people, while many others remain...
Fisherman Hospitalized After Bear Attack During Colorado Fishing Trip
A fisherman in Colorado is hospitalized after a bear attacks him during a fishing trip, leaving him with severe injuries...